Video
Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers
Author(s):
Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.
Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists regarding the field of genitourinary malignancies.
Community oncologists should focus on the results of the STAMPEDE and CHAARTED studies, which demonstrate level one evidence that patients with newly diagnosed metastatic prostate cancer who receive docetaxel in combination with androgen deprivation therapy (ADT) have a significant overall survival benefit. With this regimen, the life expectancy is increased from 1 year to nearly 1.5 years, Kibel explains.
Secondly, it is important to treat patients who develop bone metastases, he adds. The number of skeletal events decreases when patients receive docetaxel and ADT, and they will also have an improved quality of life.
<<<
